Treatment strategies and issues in low/intermediate-1 - Risk myelodysplastic syndrome (MDS) patients

Seminars in Oncology

Volumn 32, Issue SUPPL. 5, 2005, Pages

  Bowen, David T ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CYTOKINE; DEFEROXAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; IMMUNOMODULATING AGENT; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY;

BLAST TRANSFORMATION; CLINICAL FEATURE; COMORBIDITY; CONSENSUS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; CYTOKINE PRODUCTION; DRUG COST; ERYTHROCYTE TRANSFUSION; HEALTH CARE COST; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HUMAN; INDUCED MUTATION; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REFRACTORY ANEMIA WITH EXCESS BLASTS; REVIEW; RISK ASSESSMENT;

EID: 23444438216     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.02.008     Document Type: Article

References (38)

1. J.E. Parker, G.J. Mufti Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes Br J Haematol 101 1998 220 230
2. W.-K. Hofmann, M. Lübbert, D. Hoelzer Myelodysplastic syndromes Hematol J 5 2004 1 8
3. E. Hellström-Lindberg Approach to anemia associated with myelodysplastic syndromes Curr Hematol Rep 2 2003 122 129
4. P. Greenberg, C. Cox, M.M. LeBeau International scoring system for evaluating prognosis in myelodysplastic syndromes [erratum appears in Blood 1998;91:1100] Blood 89 1997 2079 2088
5. E. Hellström-Lindberg Treatment of adult myelodysplastic syndromes Int J Hematol 70 1999 141 154
6. M. Cazzola, J.E. Anderson, A. Ganser A patient-oriented approach to treatment of myelodysplastic syndromes Haematologica 83 1998 910 935
7. P. Fenaux Myelodysplastic syndromes: From pathogenesis and prognosis to treatment Semin Hematol 41 2004 6 12 (suppl 4)
8. A.F. List New approaches to the treatment of myelodysplasia Oncologist 7 2002 39 49 (suppl 1)
9. D. Bowen, D. Culligan, S. Jowitt Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes Br J Haematol 120 2003 187 200
10. National Comprehensive Cancer Network (NCCN) Myelodysplastic Panel Members: NCCN practice guidelines: Myelodysplastic syndromes v1. 2005. Available at: http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf. (accessed February 16, 2005)
11. B.D. Cheson, J.M. Bennett, H. Kantarjian Report of an international working group to standardize response criteria for myelodysplastic syndromes Blood 96 2000 3671 3674
12. E. Hellström-Lindberg, N. Gulbrandsen, G. Lindberg A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: Significant effects on quality of life Br J Haematol 120 2003 1037 1046
13. C. Rosenfeld, A. List A hypothesis for the pathogenesis of myelodysplastic syndromes: Implications for new therapies Leukemia 14 2000 2 8
14. V. Shetty, S. Mundle, S. Alvi Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes Leuk Res 20 1996 891 900
15. W.T. Bellamy, L. Richter, D. Sirjani Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes Blood 97 2001 1427 1434
16. A. Aguayo The role of angiogenesis in the biology and therapy of myelodysplastic syndromes Curr Hematol Rep 3 2004 184 191
17. D.L. Patrick, D.D. Gagnon, M.J. Zagari Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa Eur J Cancer 39 2003 335 345
18. N. Casadevall, P. Durieux, S. Dubois Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: A randomized, control trial Blood 104 2004 321 327
19. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes: A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes Br J Haematol 103 1998 1070 1074
20. Garypidou V, Verrou E, Vakalopoulou S,, et al. Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. Br J Haematol 123:958-2003
21. P. Musto, A. Falcone, G. Sanpaolo Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes Br J Haematol 122 2003 269 271
22. W. Cheung, N. Minton, K. Gunawardena Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly Eur J Clin Pharmacol 57 2001 411 418
23. E. Terpos, A. Mougiou, A. Kouraklis Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: A phase II trial in 281 patients Br J Haematol 118 2002 174 180
24. β profiles Br J Haematol 102 1998 1314 1322
25. J.J. Molldrem, E. Leifer, E. Bahceci Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes Ann Intern Med 137 2002 156 163
26. S.B. Killick, G. Mufti, J.D. Cavenagh A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia Br J Haematol 120 2003 679 684
27. Y. Saunthararajah, R. Nakamura, R. Wesley A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome Blood 102 2003 3025 3027
28. L.R. Silverman, E.P. Demakos, B.L. Peterson Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B J Clin Oncol 20 2002 2429 2440
29. P. Wijermans, M. Lübbert, G. Verhoef Low-dose 5-aza-2'- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients J Clin Oncol 18 2000 956 962
30. N. Vey Arsenic trioxide for the treatment of myelodysplastic syndromes Expert Opin Pharmacother 5 2004 613 621
31. F.C. Dougherty, B. Reigner, P. Jordan CERA (continuous erythropoiesis receptor activator) demonstrates does-dependent activity and is well tolerated in phase 1 multiple ascending dose studies Blood 102 2003 204a (abstr 713)
32. R. Smith Applications of darbepoietin-α, a novel erythropoiesis-stimulating protein, in oncology Curr Opin Hematol 9 2002 228 233
33. A. Kuendgen, C. Strupp, M. Aivado Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid Blood 104 2004 1266 1269
34. J.B. Bartlett, K. Dredge, A.G. Dalgleish The evolution of thalidomide and its IMiD derivatives as anticancer agents Nat Rev Cancer 4 2004 314 322
35. P. Musto Thalidomide therapy for myelodysplastic syndromes: Current status and future perspectives Leuk Res 28 2004 325 332
36. C. Strupp, U. Germing, M. Aivado Thalidomide for the treatment of patients with myelodysplastic syndromes Leukemia 16 2002 1 6
37. A. Raza, P. Meyer, D. Dutt Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes Blood 98 2001 958 965
38. A. List, S. Kurtin, D.J. Roe Efficacy of lenalidomide in myelodysplastic syndromes N Engl J Med 352 2005 549 557